<DOC>
	<DOCNO>NCT00025142</DOCNO>
	<brief_summary>RATIONALE : Biological therapy gefitinib may interfere growth tumor cell slow growth tumor . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug gefitinib may kill tumor cell . PURPOSE : Phase II trial study effectiveness gefitinib oxaliplatin combine leucovorin fluorouracil treat patient advance solid tumor colorectal cancer .</brief_summary>
	<brief_title>Gefitinib Combination Chemotherapy Treating Patients With Advanced Solid Tumors Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose gefitinib oxaliplatin combine fluorouracil leucovorin calcium patient advance solid tumor . ( Phase I ) ( Phase I close 5/30/02 ) - Determine pharmacokinetics pharmacodynamics regimen patient . - Determine dose-limiting toxic effect toxic effect regimen patient . - Determine antitumor response patient advance colorectal adenocarcinoma treat regimen . ( Phase II ) - Determine overall survival time progression patient advance colorectal adenocarcinoma treat regimen . ( Phase II ) - Determine presence polymorphisms genetic alteration gene implicate action regimen determine possible relationship toxic effect antitumor response regimen patient . OUTLINE : This dose-escalation study gefitinib oxaliplatin ( L-OHP ) . - Phase I ( close 5/30/02 ) : Patients receive L-OHP IV 2 hour day 1 leucovorin calcium ( CF ) IV 2 hour follow fluorouracil ( 5-FU ) IV bolus 5-FU IV 22 hour day 1 2 course . Beginning course 2 , patient also receive oral gefitinib daily day 1-14 . Courses repeat every 2 week absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) receive 2 additional course past CR . Sequential dose escalation gefitinib follow sequential dose escalation L-OHP . Cohorts 3-6 patient receive escalate dos gefitinib L-OHP maximum tolerate dose ( MTD ) combination determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . - Phase II : Patients stratify accord prior therapy : - Stratum A : Received prior therapy receive adjuvant 5-FU/CF adjuvant 5-FU/CF/irinotecan least 6 month ago - Stratum B : Received prior therapy metastatic disease receive adjuvant 5-FU/CF few 6 month ago prior irinotecan Patients receive therapy phase I ( close 5/30/02 ) L-OHP gefitinib recommend phase II dose . PROJECTED ACCRUAL : Approximately 12-15 patient accrued phase I study within 4-6 month ( Phase I close 5/30/02 ) . A total 30-81 patient ( 18-46 stratum A 12-35 stratum B ) accrue phase II study within 18 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Phase I ( close 5/30/02 ) : Histologically confirm metastatic unresectable solid tumor standard curative palliative measure exist longer effective Phase II : Histologically confirm metastatic unresectable colorectal adenocarcinoma Measurable disease assessable nonmeasurable disease ( include ascites , pleural/pericardial effusion , lymphangitis cutis/pulmonis , inflammatory breast disease , abdominal mass ( follow CT scan/MRI ) , cystic lesion ) Disease characterize elevate serum tumor marker allow No known brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 OR Karnofsky 60100 % Life expectancy : More 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm ^3 Hepatic : Bilirubin great 1.5 mg/dL AST/ALT great 2.5 time upper limit normal Renal : Creatinine normal OR Creatinine clearance least 60 mL/min Cardiovascular : No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No ongoing active infection No peripheral neuropathy No prior allergic reaction compound similar chemical biologic composition gefitinib study agents No concurrent uncontrolled illness No psychiatric illness social situation would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy : No prior bone marrow stem cell support highdose chemotherapy At least 24 hour since prior colonystimulating growth factor Chemotherapy : See Biologic therapy At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No 3 prior chemotherapy regimen Endocrine therapy : At least 2 week since prior hormonal therapy except megestrol anorexia/cachexia Radiotherapy : No prior pelvic whole abdominal radiotherapy At least 4 week since prior radiotherapy recover Surgery : At least 4 week since prior major surgery ( e.g. , laparotomy ) recover Other : At least 4 week since prior investigational therapy No concurrent investigational commercial anticancer agent No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2005</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>